{
  "epistasis_pairs": {
    "CYP2D6_loss+CYP3A4_rs776746_TT": {
      "weight": 0.45,
      "evidence": [
        "Combined CYP2D6 and CYP3A4 impairment severely reduces codeine activation",
        "PharmGKB Level 1A: Poor metabolizers at high risk for treatment failure"
      ],
      "drugs": ["codeine"]
    },
    "CYP2D6_loss+CYP3A4_reduced": {
      "weight": 0.35,
      "evidence": [
        "Dual pathway impairment increases risk of inadequate analgesia",
        "Consider alternative opioid or dose adjustment"
      ],
      "drugs": ["codeine"]
    },
    "CYP2C19_loss+CYP3A4_reduced": {
      "weight": 0.40,
      "evidence": [
        "Clopidogrel activation significantly impaired with dual enzyme deficiency",
        "FDA boxed warning for poor CYP2C19 metabolizers"
      ],
      "drugs": ["clopidogrel"]
    },
    "CYP2C9_loss+VKORC1_low_dose": {
      "weight": 0.50,
      "evidence": [
        "Warfarin sensitivity markedly increased; high bleeding risk",
        "Requires substantial dose reduction per CPIC guidelines"
      ],
      "drugs": ["warfarin"]
    },
    "SLCO1B1_reduced+CYP3A4_reduced": {
      "weight": 0.38,
      "evidence": [
        "Increased simvastatin exposure and myopathy risk",
        "Consider lower dose or alternative statin"
      ],
      "drugs": ["simvastatin"]
    }
  },
  "single_tags": {
    "CYP2D6_loss": {
      "weight": 0.30,
      "evidence": [
        "Complete loss of CYP2D6 function affects ~7% of Caucasians",
        "Critical for codeine, tramadol, and many antidepressants"
      ]
    },
    "CYP2D6_reduced": {
      "weight": 0.15,
      "evidence": [
        "Intermediate metabolizer status",
        "May require dose adjustment for CYP2D6 substrates"
      ]
    },
    "CYP2C19_loss": {
      "weight": 0.28,
      "evidence": [
        "Poor metabolizer phenotype for clopidogrel and PPIs",
        "FDA boxed warning for clopidogrel in poor metabolizers"
      ]
    },
    "CYP2C19_reduced": {
      "weight": 0.14,
      "evidence": [
        "Intermediate metabolizer status",
        "Reduced activation of prodrugs"
      ]
    },
    "CYP2C19_ultrarapid": {
      "weight": 0.10,
      "evidence": [
        "Increased metabolism may reduce efficacy of some drugs",
        "May require higher doses of PPIs"
      ]
    },
    "CYP3A4_rs776746_TT": {
      "weight": 0.18,
      "evidence": [
        "Reduced CYP3A4 expression",
        "Affects many commonly prescribed medications"
      ]
    },
    "CYP3A4_reduced": {
      "weight": 0.12,
      "evidence": [
        "Intermediate CYP3A4 function",
        "Monitor for drug accumulation"
      ]
    },
    "CYP2C9_loss": {
      "weight": 0.32,
      "evidence": [
        "High warfarin sensitivity",
        "Increased bleeding risk with standard dosing"
      ]
    },
    "CYP2C9_reduced": {
      "weight": 0.18,
      "evidence": [
        "Intermediate metabolizer for warfarin and NSAIDs",
        "Dose reduction often required"
      ]
    },
    "VKORC1_low_dose": {
      "weight": 0.22,
      "evidence": [
        "Increased warfarin sensitivity",
        "Requires lower maintenance dose"
      ]
    },
    "SLCO1B1_reduced": {
      "weight": 0.25,
      "evidence": [
        "Increased statin myopathy risk",
        "CPIC recommendation: consider alternative or lower dose"
      ]
    },
    "ABCB1_reduced_function": {
      "weight": 0.10,
      "evidence": [
        "Altered drug transport",
        "May affect bioavailability of many drugs"
      ]
    }
  },
  "pathway_burden": {
    "weight": 0.20,
    "evidence": [
      "Multiple gene impairment in same pathway indicates higher risk",
      "Redundancy loss increases susceptibility to adverse events"
    ]
  }
}

